Jonathan Dorfman - 02 Nov 2026 Form 3 Insider Report for Teladoc Health, Inc. (TDOC)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
03 Nov 2026, 16:05:12 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Dorfman
Filing notes and source

Key filing fact

Jonathan Dorfman filed Form 3 for Teladoc Health, Inc. (TDOC) on 03 Nov 2026.

Key facts

  • This page summarizes Jonathan Dorfman's Form 3 filing for Teladoc Health, Inc. (TDOC).
  • 0 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 16:05.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002157579 Primary reporting owner

Dorfman Jonathan

Relationship
Chief Legal Officer, Secretary
Address
C/O TELADOC HEALTH, INC.,, 155 E 44TH ST, SUITE 1700, NEW YORK
Signature
/s/ Jonathan Dorfman
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TDOC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,773
Date
02 Nov 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TDOC holding Derivative

Performance Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
232
Exercise price
Footnotes
F1, F2
TDOC holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,668
Exercise price
Footnotes
F3, F4
TDOC holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,500
Exercise price
Footnotes
F4, F5
TDOC holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,001
Exercise price
Footnotes
F4, F6
TDOC holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
10,000
Exercise price
Footnotes
F4, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

On March 1, 2026, the reporting person earned 232 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Footnote F2

Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

Footnote F3

On March 19, 2024, the reporting person was granted 10,000 restricted stock units, vesting one-third on March 19, 2025, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

Footnote F4

Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

Footnote F5

On March 1, 2025, the reporting person was granted 7,500 restricted stock units, vesting in full on March 1, 2028.

Footnote F6

On March 1, 2025, the reporting person was granted 10,000 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Footnote F7

On March 1, 2026, the reporting person was granted 10,00 restricted stock units, vesting one-third on March 1, 2027, with the remainder vesting in eight substantially equal quarterly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .